HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (�Regencell� or the �Company�), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people�s immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective December 1, 2021).
MSCI Inc., a leading provider of research-based indexes and analytics, announced Regencell�s addition on November 11, 2021, following results of their semi-annual index review. Launched on December 1, 2010, the MSCI World Micro Cap Index captures micro-cap representation across 23 Developed Markets countries. With 6,192 constituents, the index covers approximately 1% of the free float-adjusted market capitalization in each country, as of October 29, 2021.
Mr. Yat-Gai Au, Regencell�s Chairman & CEO noted, �We are pleased to be included in the 2021 MSCI World Micro Cap Index as we believe this international index is a benchmark for institutions investing in global micro caps. 2021 has been an exciting year for Regencell, and we expect this new milestone to increase our visibility with investors that refer to MSCI indexes as a key part of their investment strategy.�
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people�s immune system such as COVID-19 (�COVID�). Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. The Company formed a joint venture to offer COVID related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. Such forward-looking statements include the business plan of the joint venture, objectives, expectations and intentions of the joint venture parties, and Regencell�s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. Investors can identify these forward-looking statements by words or phrases such as �may,� �will,� �expect,� �anticipate,� �aim,� �estimate,� �intend,� �plan,� �believe,� �potential,� �continue,� �is/are likely to� or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty about the spread of the COVID-19 virus and the impact it will have on expected operations of the joint venture, the demand for the planned COVID TCM treatments. These and other risks and uncertainties are detailed in the other public filings with the Securities and Exchange Commission (the �SEC�) by Regencell.
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company�s registration statement and in its other filings with the SEC.
Contacts
For more information:
Corporate:
James Chung
COO & CSO
Regencell Bioscience Holdings Limited
[email protected]
Investors outside of Asia Region:
Lena Cati
The Equity Group Inc.
Vice President
(212) 836-9611
[email protected]
Investors in Asia Region:
Strategic Financial Relations Limited
Vicky Lee (852) 2864 4834
Brigid Lee (852) 2114 4313
Yvonne Lee (852) 2864 4847
[email protected]
